Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has a clinical diagnosis of stable plaque psoriasis
Subject has an ODS score for the Treatment Area of 3 or 4 at study start
You may not be if
Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.
Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.
Subject has used any phototherapy, photo-chemotherapy or systemic corticosteroid therapy within 30 days prior to study start
Subject has used any systemic methotrexate, retinoids, cyclosporine or analogous products within 90 days prior to study start
Subject has used any systemic biologic therapy for the treatment of psoriasis within 5 half-lives of the biologic prior to study start
Subject had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to study start
Subject has used topical body (excluding the scalp) psoriasis therapy including coal tar, anthralin, steroids, retinoids, vitamin D analogs (e.g., Dovonex®) within 14 days prior to study start
Subject has used emollients/moisturizers on areas to be treated within four hours prior to clinical evaluation at study start
Subject is currently using lithium or Plaquenil (hydroxychloroquine)
Subject is currently using a beta-blocking medication (e.g., propranolol) or ACE (e.g., lisinopril) inhibitor at a dose that has not been stabilized
Subject is pregnant, lactating, or is planning to become pregnant during the study
Subject is currently enrolled in an investigational drug or device study
Subject has used an investigational drug or investigational device treatment within 30 days prior to study start
Subject has been previously enrolled in this study and treated with a test article
